PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been approved to treat dyslipidaemia. However, there is a lack of knowledge on the most efficient PCSK9 therapies that target PCSK9 for secondary prevention in subjects at high risk for cardiovascular (CV) events. Thus, this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Bodapati, Adi prasad, Hanif, Ayesha, Okafor, Donatus K, Katyal, Gitika, Kaur, Gursharan, Ashraf, Hafsa, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626223/
https://www.ncbi.nlm.nih.gov/pubmed/37937036
http://dx.doi.org/10.7759/cureus.46605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626223/
https://www.ncbi.nlm.nih.gov/pubmed/37937036
http://dx.doi.org/10.7759/cureus.46605

Ejemplares similares